Target intelligence / Profile preview

Adeno-associated virus 2 (AAV2) receptor complex

Molecular classification
Receptor, Glycan, Cell surface protein, Integrin, Growth factor receptor
01

Overview

The Adeno-associated virus 2 (AAV2) receptor complex is a multi-component system on the host cell surface that mediates the attachment and entry of AAV2 capsids. The primary attachment factor is heparan sulfate proteoglycan (HSPG), a ubiquitous glycan that captures the virus and concentrates it on the cell membrane (Summerford and Samulski, 1998). Following attachment, the virus interacts with the essential protein receptor, adeno-associated virus receptor (AAVR, also known as KIAA0319L), which is required for internalization and trafficking through the endosomal system (Pillay et al., 2016). Several co-receptors, including fibroblast growth factor receptor 1 (FGFR1), hepatocyte growth factor receptor (c-Met), and various integrins (e.g., alphaVbeta5 and alpha5beta1), further facilitate the entry process (Qing et al., 1999; Summerford et al., 1999; Kashiwakura et al., 2005). This receptor complex is a fundamental target for gene therapy, as AAV2 is the most extensively studied serotype and serves as the basis for numerous therapeutic vectors, such as voretigene neparvovec (Luxturna) for retinal dystrophy. Engineering the capsid to modulate its affinity for these receptors is a key strategy for improving the safety and efficacy of AAV-based medicines by enhancing tissue specificity and reducing off-target effects.

Other names
AAV2 entry factorsAAV2 attachment factorsAAV2 receptorsHSPG and AAVR complexKIAA0319L and HSPG
02

Mechanism of action

The AAV2 capsid binds to heparan sulfate proteoglycans (HSPG) for initial attachment, followed by interaction with the adeno-associated virus receptor (AAVR) and co-receptors (e.g., FGFR1, integrins) to trigger clathrin-mediated endocytosis and subsequent nuclear trafficking for genome delivery.

03

Biological functions

Viral entryCellular attachmentEndocytosisIntracellular trafficking
04

Disease associations

Genetic diseaseInfection
05

Safety considerations

Pre-existing neutralizing antibodies (NAbs)Broad tissue tropism leading to off-target effectsDose-dependent immune responses to the viral capsid
06

Interacting drugs

Voretigene neparvovec
07

Biomarkers

Heparan sulfate proteoglycan (HSPG) expressionAdeno-associated virus receptor (AAVR/KIAA0319L) expressionAnti-AAV2 neutralizing antibody (NAb) titers

Beyond the preview

Go deeper on Adeno-associated virus 2 (AAV2) receptor complex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adeno-associated virus 2 (AAV2) receptor complex.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call